AMLX — Amylyx Pharmaceuticals, Inc.

Open full analysis

Chart, dilution, float and news for AMLX in the TickerWise workspace.

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Company profile

• Sector: Healthcare
• Industry: Biotechnology
• Country: US
• Exchange: NASDAQ
• Employees: 123
• Website: https://amylyx.com

Latest SEC filings for AMLX

• 2026-09-088-K
• 2026-08-20424B5
• 2026-08-20424B5
• 2026-08-208-K
• 2026-08-188-K
• 2026-08-18424B5
• 2026-08-18424B5
• 2026-08-188-K
• 2026-08-068-K
• 2026-08-0610-Q

Latest AMLX news

• 2026-10-06Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting Read article
• 2026-10-04Dyadic International (NASDAQ:DYAI) & Amylyx Pharmaceuticals (NASDAQ:AMLX) Critical Review Read article
• 2026-10-03Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment Read article

Open full analysis

Educational tool only — not investment advice.